Skip to content. | Skip to navigation

Personal tools

You are here: Home / Lab's life / Thesis & Co / Archives - defenses / Thesis defense: Wenyue GUAN

Thesis defense: Wenyue GUAN

When Jul 06, 2017
from 02:00 to 05:00
Contact Name
Contact Phone 0426731331
Attendees Dr Cécile ROCHETTE-EGLY, Directrice de recherche, IGBMC
Dr Gilles SALBERT, Professeur des Universités, Université de Rennes 1
Dr Jiemin WONG, Professeur des Universités, ECNU
Dr Karine Gauthier, Chargée de recherche, ENS de Lyon
Dr Laurent SACHS, Directeur de recherche, MNHN
Dr Philippe BOUVET, Professeur, ENS de Lyon
Add event to calendar vCal

On 6th of July Wenyue GUAN from team of Frédéric FLAMANT ("Functional genomics of thyroid signaling") will defend her thesis entitled: 

"TET Proteins, New Cofactors for Nuclear Receptors''


This event is scheduled at 02:00 PM in Salle des Thèses Chantal Rabourdin-Combe (ENS, Monod campus).



Thyroid hormone (T3) controls both developmental and physiological processes. Its nuclear receptors, thyroid hormone receptors (TRs), are members of the nuclear hormone receptor family which act as ligand-dependent transcription factors. DNA methylation at the fifth position of cytosine is an important epigenetic modification that affects chromatin structure and gene expression. Recent studies have established a critical function of the Ten-eleven translocation (TET) family proteins in regulating DNA methylation dynamics by converting 5-methyl-cytosine (5mC) into 5-hydroxymethylcytosine (5hmC). Studies demonstrated that TETs proteins (including TET1, TET2 and TET3) possess catalytic activity dependent and independent transcriptional regulatory functions. Our study identified TET3 as a new TR interacting protein. The AF2 domain of TR and the catalytic domain and CXXC domain of TET3 are responsible for their interaction. This interaction allows the stabilization of chromatin bound TR, resulting in a potentiation of its transcriptional activity. The modulation effect of TET3 on TR presented here is independent of its hydroxylase activity.  Thus this study evidences a new mode of action for TET3 as a non-classical regulator of TR, modulating its stability and access to chromatin rather that its intrinsic transcriptional activity. Mutations in TRa cause the RTHa symptom which severity varies with the particular mutation. The differential ability of different TRα mutants, relevant for the human RTHα disease, to interact with TET3 might explain their differential dominant negative activity. The regulatory function of TET3 might be more general towards the nuclear receptor transcriptional factors since different members of the superfamily present the same interaction with TET3, such as AR (androgen receptor), ERR (Estrogen-related receptor) and RAR (retinoic acid receptor). The interaction between TET3 and RAR involves the DNA binding domain of RAR. The functional relevance of TET3/RAR interaction was further studied in ES cells. Combined deficiency of all three TETs led to depletion of 5hmC and deregulation of genes involved in ES differentiation. Among the deregulated genes, a subset of RA response genes was identified, suggesting that RARs (retinoic acid receptors) and TETs might work together to regulate ES cell differentiation. Further dissection revealed that TET proteins may have a role in facilitating RAR recruitment to the promoter regions of these RAR target genes. Moreover, our results indicated a potential role of the hydroxylase activity of TET proteins in modulating RAR transcriptional activity. Altogether, our work identified TET proteins as new regulators of NR (Nuclear Receptors). The exact mechanisms involved need to be further studied.


Key words: Thyroid Hormone Receptor (TR), Methylcytosine dioxygenase TET3, Protein Stability, Chromatin recruitment, RTHa syndrome, Retinoic acid receptor (RAR).